<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01399749</url>
  </required_header>
  <id_info>
    <org_study_id>HLPTRA-2009-01</org_study_id>
    <secondary_id>2009-016628-29</secondary_id>
    <nct_id>NCT01399749</nct_id>
  </id_info>
  <brief_title>Autologous Mesenchymal Stem Cells vs. Chondrocytes for the Repair of Chondral Knee Defects</brief_title>
  <acronym>ASCROD</acronym>
  <official_title>A Comparative Clinical Trial for the Repair of Chondral Knee Defects: Transplantation of Autologous Cultured Chondrocytes vs. Autologous Mesenchymal Stem Cells Derived From Adipose Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of our study is to compare the safety and effectiveness of the use of
      autologous cultured adipose tissue-derived stem cells versus cultured autologous chondrocytes
      for the treatment of chondral knee lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chondral knee lesions are frequent and produce important functional limitations and arthrosis
      development. Arthrosis is one of the most important causes of disability and its treatment
      with prosthetic surgery is associated with a high cost, and is not free of other
      complications. Several studies of cell therapy with autologous chondrocytes have shown
      efficacy in the treatment of this type of lesions, and currently is a common technique for
      the treatment of focal lesions of articular cartilage. Autologous chondrocyte transplant is
      associated with morbidity of the cartilage sample removal, which needs intra-articular
      surgery, and the limited tissue sample for culture. Adipose tissue-derived mesenchymal stem
      cells (ASC) have demonstrated chondrocytic differentiation and have been used in animal
      models for articular cartilage repair. Adipose tissue yields more ASC than chondrocytes are
      obtained from cartilage, and liposuction is simple and with less adverse events than
      arthroscopy. It is worth mentioned that culture conditions are less stringent for ASC than
      for chondrocytes, in terms of number of passages to obtain the amount of cells needed for
      implantation.

      We propose a randomized clinical trial, in which we compare the surgical implantation of
      either autologous chondrocytes or autologous ASC to treat chondral knee lesions.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyaline cartilage production for chondral knee lesions repair</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Clinical evolution</measure>
    <time_frame>18 months</time_frame>
    <description>Changes in Clinical tests and SF-12 Health Survey over 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Functional evolution</measure>
    <time_frame>18 months</time_frame>
    <description>Changes in Western Ontario-McMaster Osteoarthritis Score(WOMAC) over 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Functional evolution</measure>
    <time_frame>18 months</time_frame>
    <description>Changes in Knee Society Score(KSS) over 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Histological evaluation</measure>
    <time_frame>18 months</time_frame>
    <description>Hyaline cartilage production by histological methods at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Radiological evaluation</measure>
    <time_frame>18 months</time_frame>
    <description>MRI at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse events</measure>
    <time_frame>18 months</time_frame>
    <description>Sistemic and local AEs especially attributable to implanted cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Acute inflammatory events</measure>
    <time_frame>18 months</time_frame>
    <description>Increase of pain of at least 30 mm on a 100 mm visual analog scale (VAS) along with self-reported swelling within 3 days post-cell application</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Articular Cartilage Lesion of the Femoral Condyle</condition>
  <arm_group>
    <arm_group_label>Autologous ASC implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with autologous ASC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous Chondrocytes implantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with autologous chondrocytes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Implantation of autologous cells</intervention_name>
    <description>Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane</description>
    <arm_group_label>Autologous ASC implantation</arm_group_label>
    <arm_group_label>Autologous Chondrocytes implantation</arm_group_label>
    <other_name>ACI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic focal articular cartilage lesion on the medial femoral condyle

          -  Lesion on femoral condyle between 1 and 5 cm²

          -  ICRS Grade III/IV

          -  Stable knee

          -  Signed patient informed consent

        Exclusion Criteria:

          -  Clinically relevant member malalignment (&gt; 5 degrees)

          -  Non stable knee

          -  Inflammatory joint disease

          -  Knee surgery in the last year (transplant, suture or resection of the meniscus,
             mosaicplasty, microfracture)

          -  Participation in concurrent trials or in the previous 3 months

          -  Subjects with hepatitis, HIV or syphilis

          -  Malignancy in the previous 5 years

          -  Alcohol and/or drug abuse

          -  Poor general health as judged by Investigator

          -  Clinically relevant second cartilage lesion on the patella

          -  Patellofemoral cartilage lesion

          -  Known allergy to gentamicin or penicillins (or presence of multiple severe allergies)

          -  Having received hyaluronic acid intra-articular injections in the affected knee within
             the last 6 months of baseline

          -  Taking specific OA drugs such as chondroitin sulfate, diacerein, n-glucosamine,
             piascledine, capsaicin within 2 weeks of the baseline visit

          -  Corticosteroid treatment by systemic or intra-articular route within the last month of
             baseline or intramuscular or oral corticosteroids within the last 2 weeks of baseline

          -  Chronic use of anticoagulants

          -  Uncontrolled diabetes

          -  Any concomitant painful or disabling disease of the spine,hips or lower limbs that
             would interfere with evaluation of the afflicted knee

          -  Any clinically significant or symptomatic vascular or neurologic disorder of the lower
             extremities

          -  Liver enzymes (SGOT, SGPT, Alkaline Phosphatase) of more then two times the upper
             limit of normal or any other result that is clinically important according to the
             Investigator

          -  CRP &gt; 10 mg/l
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alonso C. Moreno Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopedic Surgery and Traumatology Department. Knee Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alonso C. Moreno Garcia, MD</last_name>
    <phone>+34 917277314</phone>
    <email>alonso.moreno.garcia@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fernando de Miguel</last_name>
    <phone>+34 912071022</phone>
    <email>fdemiguel.hulp@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>La Paz University Hospital. Orthopedic Surgery and Traumatology Department, Knee Unit; Cell Therapy Laboratory.</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alonso C. Moreno Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose L. Leal Helmling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Santiago Bello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando de Miguel, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damian Garcia-Olmo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariano A. Garcia-Arranz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med. 1994 Oct 6;331(14):889-95.</citation>
    <PMID>8078550</PMID>
  </reference>
  <reference>
    <citation>Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage. 2002 Mar;10(3):199-206.</citation>
    <PMID>11869080</PMID>
  </reference>
  <reference>
    <citation>García-Gómez I, Elvira G, Zapata AG, Lamana ML, Ramírez M, Castro JG, Arranz MG, Vicente A, Bueren J, García-Olmo D. Mesenchymal stem cells: biological properties and clinical applications. Expert Opin Biol Ther. 2010 Oct;10(10):1453-68. doi: 10.1517/14712598.2010.519333. Review.</citation>
    <PMID>20831449</PMID>
  </reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <last_update_submitted>July 21, 2011</last_update_submitted>
  <last_update_submitted_qc>July 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alonso C. Moreno Garcia</name_title>
    <organization>La Paz University Hospital. Orthopedic Surgery and Traumatology Department</organization>
  </responsible_party>
  <keyword>Cartilage</keyword>
  <keyword>Articular</keyword>
  <keyword>Femoral</keyword>
  <keyword>Knee</keyword>
  <keyword>Chondrocytes</keyword>
  <keyword>Adipose tissue-derived mesenchymal stem cells</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

